IceCure Medical Ltd. (Nasdaq: ICCM) announced that Adventist Health Glendale in Glendale, California, has signed an agreement and received Institutional Review Board approval to become the first clinical site to enroll patients in the company's post-marketing "ChoICE" study.

The study evaluates the company's ProSense® cryoablation system combined with endocrine therapy for low-risk, early-stage breast cancer in patients aged 70 and older with tumors no larger than 1.5 cm. The FDA authorized ProSense® for this indication in October 2025.

The ChoICE study plans to enroll up to 400 patients across 30 U.S. sites. The study design allows participating sites to simultaneously enroll study patients and treat eligible patients outside the trial under a commercial pathway.

The Adventist Health Glendale site will be led by Dr. Dennis Holmes, MD, FACS, a breast surgeon with research experience in breast cancer cryoablation.

"Cryoablation may offer a less invasive approach for carefully selected patients, and the ChoICE Study will help further evaluate its use in real-world clinical practice, including follow-up assessment and adherence to endocrine therapy," Dr. Holmes said in a statement.

Eyal Shamir, chief executive officer of IceCure Medical, said the site brings "strong clinical infrastructure and breast care expertise" to the study.

Adventist Health Glendale is a 515-bed nonprofit medical center. IceCure Medical, based in Caesarea, Israel, develops liquid-nitrogen-based cryoablation systems targeting breast, kidney, bone, and lung cancer.